Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study

Cardiology Journal

Volumn 20, Issue 5, 2013, Pages 545-551

  Rosiak, Marek ^a   Postula, Marek ^a   Kaplon Cieslicka, Agnieszka ^a   Kondracka, Agnieszka ^a   Trzepla, Ewa ^a   Czlonkowski, Andrzej ^a   Janicki, Piotr K ^b   Filipiak, Krzysztof J ^a   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet; Cardiovascular; Inflammation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; COLLAGEN; INFLAMMATORY MARKER; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PLATELET REACTIVITY; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION ANALYZER; TREATMENT DURATION;

ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CD40 LIGAND; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLAND; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885216489     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0045     Document Type: Article

References (36)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:epidemiology, pathophysiology, and management. JAMA, 2002;287: 2570-2581.
2. Yazbek N, Bapat A, Kleiman N. Platelet abnormalities in diabetes mellitus. Coron Artery Dis, 2003; 14: 365-371.
3. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res, 2010; 7: 251-259.
4. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol, 2000; 121: 437-443.
5. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatmenton soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation, 2003; 107: 1954-1957.
6. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome: The Chennai Urban Rural Epidemiology Study. Metabolism, 2006; 55: 237-242.
7. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation, 2001; 104: 2266-2268.
8. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation, 2001; 103: 491-495.
9. Hovens MM, Snoep JD, Groeneveld Y, Frolich M, Tamsma JT, Huisman MV. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: A randomized placebo-controlled crossover trial. Diabetes Obes Metab, 2008; 10: 668-674.
10. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes, 2006; 55: 780-784.
11. Standards of medical care in diabetes: 2012. Diabetes Care, 2012; 35 (suppl. 1): S11-S63
12. Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost, 2007; 5: 2197-2203
13. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res, 2010; 126: e318-e322.
14. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv, 2011; 4: 180-187.
15. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin--Induced Platelet Effect (ASPECT) study. Circulation, 2007; 115: 3156-3164.
16. Rosiak M, Postula M, Kaplon-Cieślicka A et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol, 2013; DOI: 10.5603/KP.2013.0056.
17. Postula M, Kaplon-Cieslicka A, Rosiak M et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: Evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost, 2011; 9: 2291-2301.
18. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 1999; 100: 793-798.
19. Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol, 2003; 92: 843-845.
20. Jennings LK. Mechanisms of platelet activation: Need for newstrategies to protect against platelet-mediated atherothrombosis.Thromb Haemost, 2009; 102: 248-257.
21. Yeh ET, Khan BV. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J ThrombHaemost, 2006; 4: 2308-2316.
22. Muhlestein JB. Effect of antiplatelet therapy on inflammatorymarkers in atherothrombotic patients. Thromb Haemost, 2010; 103: 71-82.
23. Azar RR, Kassab R, Zoghbi A et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J, 2006; 151: 521 e1-e4.
24. Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol, 2008; 52: 1826-1833
25. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ, 2007; 16 (suppl. 3): S17-S28.
26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 336: 973-979.
27. Herder C, Schottker B, Rothenbacher D et al. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: Results from the ESTHER study. Atherosclerosis, 2011; 216: 244-247.
28. Cox AJ, Agarwal S, Herrington DM, Carr JJ, Freedman BI, Bowden DW. C-reactive protein concentration predicts mortality in type 2 diabetes: The Diabetes Heart Study. Diabet Med, 2011
29. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta--analysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860.
30. Yip HK, Hang CL, Fang CY et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest, 2005; 127: 803-808.
31. Shi JZ, Wang LY, Zhu Y et al. OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina. J Int Med Res, 2011; 39: 1275-1283.
32. Hejase de Trad C. Soluble CD40L versus myocyte enhancer factor: Predicting a prominent marker for cardiovascular disease. Conf Proc IEEE Eng Med Biol Soc, 2006; 1: 1698-1701.
33. Yan J, Wu Z, Huang Z, Li L, Zhong R, Kong X. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J, 2002; 115: 491-493.
34. Tousoulis D, Androulakis E, Papageorgiou N et al. From atherosclerosis to acute coronary syndromes: The role of soluble CD40 ligand. Trends Cardiovasc Med, 2010; 20: 153-164.
35. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol, 2009; 103: 20A-26A.
36. Harrison P, Frelinger AL, III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res, 2007; 120: 323-336.